article Open AccessTop 1% cited
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
The Lancet · 2018 · Vol. 391(10126) · pp. 1163–1173
Masatoshi Kudo✉(Kindai University)Richard S. FinnShukui Qin(81th Hospital of PLA)Kwang‐Hyub Han(Severance Hospital)Kenji Ikeda(Toranomon Hospital)Fabio Piscaglia(University of Bologna)Ari David Baron(California Pacific Medical Center)Joong‐Won Park(National Cancer Center)Guohong Han(Air Force Medical University)Jacek Jassem(Gdańsk Medical University)Jean Frédéric Blanc(Université de Bordeaux)Arndt Vogel(Medizinische Hochschule Hannover)Д. В. Комов(Russian Cancer Research Center NN Blokhin)T.R. Jeffry Evans(University of Glasgow)Carlos López(Marqués de Valdecilla University Hospital)Corina E. Dutcus(Eisai (United States))Matthew Guo(Eisai (United States))Kenichi Saito(Eisai (United States))Silvija Kraljevic(Eisai (United Kingdom))Toshiyuki Tamai(Eisai (United States))Min Ren(Eisai (United States))Ann‐Lii Cheng(National Taiwan University Hospital)
Hepatocellular Carcinoma Treatment and PrognosisLiver Disease Diagnosis and TreatmentLiver physiology and pathologyLenvatinibSorafenibHepatocellular carcinomaMedicineInternal medicineOncology
MeSH terms
SorafenibAgedAntineoplastic AgentsFemaleCarcinoma, HepatocellularHumansLiver NeoplasmsMaleMiddle AgedNiacinamidePhenylurea CompoundsQuinolinesSurvival RateTreatment Outcome
Funding
- Eisai Incorporated
Citations
5,305
FWCI
263.96
field-weighted impact
References
32
Percentile
100%
vs. same field & year
Citations per year
Cited by
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
Hepatology · 2018 · 4,515 citations
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Journal of Hepatology · 2018 · 11,335 citations
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
New England Journal of Medicine · 2020 · 6,911 citations
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Hepatology · 2023 · 1,480 citations
Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh A Liver Function: A Proof-Of-Concept Study
Cancers · 2019 · 293 citations
Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment
Cells · 2020 · 489 citations
Hepatocellular carcinoma
The Lancet · 2018 · 5,512 citations
References
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
International Journal of Cancer · 2014 · 28,948 citations
Sorafenib in Advanced Hepatocellular Carcinoma
New England Journal of Medicine · 2008 · 12,835 citations
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
The Lancet Oncology · 2008 · 5,801 citations
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
European Journal of Cancer · 2008 · 28,935 citations
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
Gastroenterology · 2007 · 5,410 citations
Management of Hepatocellular Carcinoma: An Update Δσ
Hepatology · 2011 · 8,095 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.